This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Berge T, Ulimoen SR, Enger S, Arnesen H, Seljeflot I, Tveit A. Impact of atrial fibrillation on inflammatory and fibrinolytic variables in the elderly. Scand J Clin Lab Invest. 2013; 73: 326–333.BergeTUlimoenSREngerSArnesenHSeljeflotITveitAImpact of atrial fibrillation on inflammatory and fibrinolytic variables in the elderlyScand J Clin Lab Invest.20137332633310.3109/00365513.2013.78009323586783Search in Google Scholar
Li CY, Zhang JR, Hu WN, Li SN. Atrial fibrosis underlying atrial fibrillation (Review). Int J Mol Med. 2021; 47: 9.LiCYZhangJRHuWNLiSNAtrial fibrosis underlying atrial fibrillation (Review)Int J Mol Med.202147910.3892/ijmm.2020.4842783495333448312Search in Google Scholar
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, et al. Heart disease and stroke statistics-2019 update: A report from the American Heart Association. Circulation. 2019; 139: e56–e528.BenjaminEJMuntnerPAlonsoABittencourtMSCallawayCWCarsonAPChamberlainAMChangARChengSDasSRHeart disease and stroke statistics-2019 update: A report from the American Heart AssociationCirculation.2019139e56e52810.1161/CIR.000000000000065930700139Search in Google Scholar
Clementy N, Piver E, Bisson A, Andre C, Bernard A, Pierre B, Fauchier L, Babuty D. Galectin-3 in atrial fibrillation: Mechanisms and therapeutic implications. Int J Mol Sci. 2018; 19: 976.ClementyNPiverEBissonAAndreCBernardAPierreBFauchierLBabutyDGalectin-3 in atrial fibrillation: Mechanisms and therapeutic implicationsInt J Mol Sci.20181997610.3390/ijms19040976597951529587379Search in Google Scholar
Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: Epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017; 120: 1501–1517.StaerkLShererJAKoDBenjaminEJHelmRHAtrial fibrillation: Epidemiology, pathophysiology, and clinical outcomesCirc Res.20171201501151710.1161/CIRCRESAHA.117.309732550087428450367Search in Google Scholar
Heidt ST, Kratz A, Najarian K, Hassett AL, Oral H, Gonzalez R, Nallamothu BK, Clauw D, Ghanbari H. Symptoms in atrial fibrillation: A contemporary review and future directions. J Atr Fibrillation. 2016; 9: 1422.HeidtSTKratzANajarianKHassettALOralHGonzalezRNallamothuBKClauwDGhanbariHSymptoms in atrial fibrillation: A contemporary review and future directionsJ Atr Fibrillation.201691422Search in Google Scholar
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021; 42: 373–498.HindricksGPotparaTDagresNArbeloEBaxJJBlomström-LundqvistCBorianiGCastellaMDanGADilaverisPE2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)Eur Heart J.20214237349810.1093/eurheartj/ehaa61232860505Search in Google Scholar
Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: A translational appraisal. Physiol Rev. 2011; 91: 265–325.SchottenUVerheuleSKirchhofPGoetteAPathophysiological mechanisms of atrial fibrillation: A translational appraisalPhysiol Rev.20119126532510.1152/physrev.00031.200921248168Search in Google Scholar
Nattel S, Harada M. Atrial remodeling and atrial fibrillation: Recent advances and translational perspectives. J Am Coll Cardiol. 2014; 63: 2335–2345.NattelSHaradaMAtrial remodeling and atrial fibrillation: Recent advances and translational perspectivesJ Am Coll Cardiol.2014632335234510.1016/j.jacc.2014.02.55524613319Search in Google Scholar
Dzeshka MS, Lip GY, Snezhitskiy V, Shantsila E. Cardiac fibrosis in patients with atrial fibrillation: Mechanisms and clinical implications. J Am Coll Cardiol. 2015; 66: 943–959.DzeshkaMSLipGYSnezhitskiyVShantsilaECardiac fibrosis in patients with atrial fibrillation: Mechanisms and clinical implicationsJ Am Coll Cardiol.20156694395910.1016/j.jacc.2015.06.131326293766Search in Google Scholar
Nattel S. Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation. JACC Clin Electrophysiol. 2017; 3: 425–435.NattelSMolecular and cellular mechanisms of atrial fibrosis in atrial fibrillationJACC Clin Electrophysiol.2017342543510.1016/j.jacep.2017.03.00229759598Search in Google Scholar
Al Ghamdi B, Hassan W. Atrial remodeling and atrial fibrillation: Mechanistic interactions and clinical implications. J Atr Fibrillation. 2009; 2: 125.Al GhamdiBHassanWAtrial remodeling and atrial fibrillation: Mechanistic interactions and clinical implicationsJ Atr Fibrillation.20092125Search in Google Scholar
Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac fibrosis: The fibroblast awakens. Circ Res. 2016; 118: 1021–1040.TraversJGKamalFARobbinsJYutzeyKEBlaxallBCCardiac fibrosis: The fibroblast awakensCirc Res.20161181021104010.1161/CIRCRESAHA.115.306565480048526987915Search in Google Scholar
Park S, Ranjbarvaziri S, Zhao P, Ardehali R. Cardiac fibrosis is associated with decreased circulating levels of full-length CILP in heart failure. JACC Basic Transl Sci. 2020; 5: 432–443.ParkSRanjbarvaziriSZhaoPArdehaliRCardiac fibrosis is associated with decreased circulating levels of full-length CILP in heart failureJACC Basic Transl Sci.2020543244310.1016/j.jacbts.2020.01.016725119332478206Search in Google Scholar
Hara H, Takeda N, Komuro I. Pathophysiology and therapeutic potential of cardiac fibrosis. Inflamm Regen. 2017; 37: 13.HaraHTakedaNKomuroIPathophysiology and therapeutic potential of cardiac fibrosisInflamm Regen.2017371310.1186/s41232-017-0046-5572592529259712Search in Google Scholar
Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014; 71: 549–574.KongPChristiaPFrangogiannisNGThe pathogenesis of cardiac fibrosisCell Mol Life Sci.20147154957410.1007/s00018-013-1349-6376948223649149Search in Google Scholar
Dobaczewski M, Frangogiannis NG. Chemokines and cardiac fibrosis. Front Biosci. 2009; 1: 391–405.DobaczewskiMFrangogiannisNGChemokines and cardiac fibrosisFront Biosci.2009139140510.2741/s33279872919482709Search in Google Scholar
Hinderer S, Schenke-Layland K. Cardiac fibrosis - A short review of causes and therapeutic strategies. Adv Drug Deliv Rev. 2019; 146: 77–82.HindererSSchenke-LaylandKCardiac fibrosis - A short review of causes and therapeutic strategiesAdv Drug Deliv Rev.2019146778210.1016/j.addr.2019.05.01131158407Search in Google Scholar
Karolko B, Przewłocka-Kosmala M. Fibrosis markers in heart failure. Folia Cardiologica. 2017; 12: 245–253.KarolkoBPrzewłocka-KosmalaMFibrosis markers in heart failureFolia Cardiologica.201712245253Search in Google Scholar
Pathak R, Lau DH, Mahajan R, Sanders P. Structural and functional remodeling of the left atrium: Clinical and therapeutic implications for atrial fibrillation. J Atr Fibrillation. 2013; 6: 986.PathakRLauDHMahajanRSandersPStructural and functional remodeling of the left atrium: Clinical and therapeutic implications for atrial fibrillationJ Atr Fibrillation.20136986Search in Google Scholar
Schoonderwoerd BA, Smit MD, Pen L, Van Gelder IC. New risk factors for atrial fibrillation: Causes of ‘not-so-lone atrial fibrillation’. Europace. 2008; 10: 668–673.SchoonderwoerdBASmitMDPenLVan GelderICNew risk factors for atrial fibrillation: Causes of ‘not-so-lone atrial fibrillation’Europace.20081066867310.1093/europace/eun12418480076Search in Google Scholar
McDowell KS, Vadakkumpadan F, Blake R, Blauer J, Plank G, Macleod RS, Trayanova NA. Mechanistic inquiry into the role of tissue remodeling in fibrotic lesions in human atrial fibrillation. Biophys J. 2013; 104: 2764–2773.McDowellKSVadakkumpadanFBlakeRBlauerJPlankGMacleodRSTrayanovaNAMechanistic inquiry into the role of tissue remodeling in fibrotic lesions in human atrial fibrillationBiophys J.20131042764277310.1016/j.bpj.2013.05.025368634623790385Search in Google Scholar
Friedrichs K, Baldus S, Klinke A. Fibrosis in atrial fibrillation - role of reactive species and MPO. Front Physiol. 2012; 3: 214.FriedrichsKBaldusSKlinkeAFibrosis in atrial fibrillation - role of reactive species and MPOFront Physiol.2012321410.3389/fphys.2012.00214337972522723783Search in Google Scholar
Ding Y, Wang Y, Zhang W, Jia Q, Wang X, Li Y, Lv S, Zhang J. Roles of biomarkers in myocardial fibrosis. Aging Dis. 2020; 11: 1157–1174.DingYWangYZhangWJiaQWangXLiYLvSZhangJRoles of biomarkers in myocardial fibrosisAging Dis.2020111157117410.14336/AD.2020.0604750525933014530Search in Google Scholar
Święcki P, Knapp M, Lisowska A. The role of galectin 3 as a diagnostic and prognostic marker in cardiology. Folia Cardiologica. 2018; 13: 29–34.ŚwięckiPKnappMLisowskaAThe role of galectin 3 as a diagnostic and prognostic marker in cardiologyFolia Cardiologica.2018132934Search in Google Scholar
Praczyk Ł, Hoffmann K, Bryl W. Galectin 3 as a biomarker in cardiovascular diseases. Hygeia Public Health. 2019; 54: 75–79.PraczykŁHoffmannKBrylWGalectin 3 as a biomarker in cardiovascular diseasesHygeia Public Health.2019547579Search in Google Scholar
da Silveira MMBM, Cabral JVB, Souza BM, Hazime LHP, Araujo SLM, Xavier AT, Mendes Filho EB, Vasconcelos LRDS, Sobral Filho DC, de Oliveira DC. How can galectin-3 as a biomarker of fibrosis improve atrial fibrillation diagnosis and prognosis? J Clin Med Res. 2020; 12: 647–654.da SilveiraMMBMCabralJVBSouzaBMHazimeLHPAraujoSLMXavierATMendes FilhoEBVasconcelosLRDSSobral FilhoDCde OliveiraDCHow can galectin-3 as a biomarker of fibrosis improve atrial fibrillation diagnosis and prognosis?J Clin Med Res.20201264765410.14740/jocmr4313752456433029271Search in Google Scholar
Pranata R, Yonas E, Chintya V, Tondas AE, Raharjo SB. Serum galectin-3 level and recurrence of atrial fibrillation post-ablation - Systematic review and meta-analysis. Indian Pacing Electrophysiol J. 2020; 20: 64–69.PranataRYonasEChintyaVTondasAERaharjoSBSerum galectin-3 level and recurrence of atrial fibrillation post-ablation - Systematic review and meta-analysisIndian Pacing Electrophysiol J.202020646910.1016/j.ipej.2020.02.002708267832081686Search in Google Scholar
Biaggi P, Ammann C, Imperiali M, Hammerer-Lercher A, Breidthardt T, Müller C, Maisel A, Ruschitzka F. Soluble ST2 – a new biomarker in heart failure. Cardiovasc Med. 2019; 22: w02008.BiaggiPAmmannCImperialiMHammerer-LercherABreidthardtTMüllerCMaiselARuschitzkaFSoluble ST2 – a new biomarker in heart failureCardiovasc Med.201922w0200810.4414/cvm.2019.02008Search in Google Scholar
Wang Z, Cheng L, Zhang J, Liang Z, Dong R, Hang F, Wang X, Wang Z, Wu Y, Du J. Serum-soluble ST2 is a novel biomarker for evaluating left atrial low-voltage zone in paroxysmal atrial fibrillation. Med Sci Monit. 2020; 26: e926221.WangZChengLZhangJLiangZDongRHangFWangXWangZWuYDuJSerum-soluble ST2 is a novel biomarker for evaluating left atrial low-voltage zone in paroxysmal atrial fibrillationMed Sci Monit.202026e92622110.12659/MSM.926221750012632898129Search in Google Scholar
Marino L, Romano GP, Santulli M, Bertazzoni G, Suppa M. Soluble sST2 biomarker analysis for fibrosis development in atrial fibrillation. A case control study. Clin Ter. 2021; 172: 145–150.MarinoLRomanoGPSantulliMBertazzoniGSuppaMSoluble sST2 biomarker analysis for fibrosis development in atrial fibrillation. A case control studyClin Ter.2021172145150Search in Google Scholar
Villacorta H, Maisel AS. Soluble ST2 testing: A promising biomarker in the management of heart failure. Arq Bras Cardiol. 2016; 106: 145–152.VillacortaHMaiselASSoluble ST2 testing: A promising biomarker in the management of heart failureArq Bras Cardiol.201610614515210.5935/abc.20150151476501326761075Search in Google Scholar
Kienesberger PC, Pulinilkunnil T, Sung MM, Nagendran J, Haemmerle G, Kershaw EE, Young ME, Light PE, Oudit GY, Zechner R, Dyck JR. Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction. Mol Cell Biol. 2012; 32: 740–750.KienesbergerPCPulinilkunnilTSungMMNagendranJHaemmerleGKershawEEYoungMELightPEOuditGYZechnerRDyckJRMyocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunctionMol Cell Biol.20123274075010.1128/MCB.06470-11327298322158969Search in Google Scholar
Pulinilkunnil T, Kienesberger PC, Nagendran J, Sharma N, Young ME, Dyck JR. Cardiac-specific adipose triglyceride lipase overexpression protects from cardiac steatosis and dilated cardiomyopathy following diet-induced obesity. Int J Obes. 2014; 38: 205–215.PulinilkunnilTKienesbergerPCNagendranJSharmaNYoungMEDyckJRCardiac-specific adipose triglyceride lipase overexpression protects from cardiac steatosis and dilated cardiomyopathy following diet-induced obesityInt J Obes.20143820521510.1038/ijo.2013.10323817015Search in Google Scholar
Radovic B, Aflaki E, Kratky D. Adipose triglyceride lipase in immune response, inflammation, and atherosclerosis. Biol Chem. 2012; 393: 1005–1011.RadovicBAflakiEKratkyDAdipose triglyceride lipase in immune response, inflammation, and atherosclerosisBiol Chem.20123931005101110.1515/hsz-2012-0192352000322944699Search in Google Scholar
Kienesberger PC, Pulinilkunnil T, Nagendran J, Young ME, Bogner-Strauss JG, Hackl H, Khadour R, Heydari E, Haemmerle G, Zechner R, et al. Early structural and metabolic cardiac remodelling in response to inducible adipose triglyceride lipase ablation. Cardiovasc Res. 2013; 99: 442–451.KienesbergerPCPulinilkunnilTNagendranJYoungMEBogner-StraussJGHacklHKhadourRHeydariEHaemmerleGZechnerREarly structural and metabolic cardiac remodelling in response to inducible adipose triglyceride lipase ablationCardiovasc Res.20139944245110.1093/cvr/cvt124371832223708736Search in Google Scholar
Kintscher U, Foryst-Ludwig A, Haemmerle G, Zechner R. The role of adipose triglyceride lipase and cytosolic lipolysis in cardiac function and heart failure. Cell Rep Med. 2020; 1: 100001.KintscherUForyst-LudwigAHaemmerleGZechnerRThe role of adipose triglyceride lipase and cytosolic lipolysis in cardiac function and heart failureCell Rep Med.2020110000110.1016/j.xcrm.2020.100001765949233205054Search in Google Scholar
Galgano M, Hampton G, Frierson H. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19: 847–853.GalganoMHamptonGFriersonHComprehensive analysis of HE4 expression in normal and malignant human tissuesMod Pathol.20061984785310.1038/modpathol.380061216607372Search in Google Scholar
LeBleu VS, Teng Y, O’Connell JT, Charytan D, Müller GA, Müller CA, Sugimoto H, Kalluri R. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med. 2013; 19: 227–231.LeBleuVSTengYO’ConnellJTCharytanDMüllerGAMüllerCASugimotoHKalluriRIdentification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosisNat Med.20131922723110.1038/nm.2989445750823353556Search in Google Scholar
Piek A, Meijers WC, Schroten NF, Gansevoort RT, de Boer RA, Silljé HH. he4 serum levels are associated with heart failure severity in patients with chronic heart failure. J Card Fail. 2017; 23: 12–19.PiekAMeijersWCSchrotenNFGansevoortRTde BoerRASilljéHHhe4 serum levels are associated with heart failure severity in patients with chronic heart failureJ Card Fail.201723121910.1016/j.cardfail.2016.05.00227224553Search in Google Scholar
Huang Y, Jiang H, Zhu L. Human epididymis protein 4 as an indicator of acute heart failure in patients with chronic kidney disease. Lab Med. 2020; 51: 169–175.HuangYJiangHZhuLHuman epididymis protein 4 as an indicator of acute heart failure in patients with chronic kidney diseaseLab Med.20205116917510.1093/labmed/lmz04131245814Search in Google Scholar
Leifheit-Nestler M, Haffner D. Paracrine effects of FGF23 on the heart. Front Endocrinol. 2018; 9: 278.Leifheit-NestlerMHaffnerDParacrine effects of FGF23 on the heartFront Endocrinol.2018927810.3389/fendo.2018.00278598531129892269Search in Google Scholar
Lee TW, Chung CC, Lee TI, Lin YK, Kao YH, Chen YJ. Fibroblast growth factor 23 stimulates cardiac fibroblast activity through phospholipase C-mediated calcium signaling. Int J Mol Sci. 2021; 23: 166.LeeTWChungCCLeeTILinYKKaoYHChenYJFibroblast growth factor 23 stimulates cardiac fibroblast activity through phospholipase C-mediated calcium signalingInt J Mol Sci.20212316610.3390/ijms23010166874515235008591Search in Google Scholar
Kuga K, Kusakari Y, Uesugi K, Semba K, Urashima T, Akaike T, Minamisawa S. Fibrosis growth factor 23 is a promoting factor for cardiac fibrosis in the presence of transforming growth factor-β1. PLoS One. 2020; 15: e0231905.KugaKKusakariYUesugiKSembaKUrashimaTAkaikeTMinamisawaSFibrosis growth factor 23 is a promoting factor for cardiac fibrosis in the presence of transforming growth factor-β1PLoS One.202015e023190510.1371/journal.pone.0231905717386032315372Search in Google Scholar
Kao YH, Chen YC, Lin YK, Shiu RJ, Chao TF, Chen SA, Chen YJ. FGF-23 dysregulates calcium homeostasis and electrophysiological properties in HL-1 atrial cells. Eur J Clin Investig. 2014; 44: 795–801.KaoYHChenYCLinYKShiuRJChaoTFChenSAChenYJFGF-23 dysregulates calcium homeostasis and electrophysiological properties in HL-1 atrial cellsEur J Clin Investig.20144479580110.1111/eci.1229624942561Search in Google Scholar
Vázquez-Sánchez S, Poveda J, Navarro-García JA, González-Lafuente L, Rodriguez-Sánchez E, Ruilope LM, Ruiz-Hurtado G. An overview of FGF-23 as a novel candidate biomarker of cardiovascular risk. Front Physiol. 2021; 12: 632260.Vázquez-SánchezSPovedaJNavarro-GarcíaJAGonzález-LafuenteLRodriguez-SánchezERuilopeLMRuiz-HurtadoGAn overview of FGF-23 as a novel candidate biomarker of cardiovascular riskFront Physiol.20211263226010.3389/fphys.2021.632260798506933767635Search in Google Scholar
Yousefi F, Shabaninejad Z, Vakili S, Derakhshan M, Movahedpour A, Dabiri H, Ghasemi Y, Mahjoubin-Tehran M, Nikoozadeh A, Savardashtaki A, et al. TGF-β and WNT signaling pathways in cardiac fibrosis: Non-coding RNAs come into focus. Cell Commun Signal. 2020; 18: 87.YousefiFShabaninejadZVakiliSDerakhshanMMovahedpourADabiriHGhasemiYMahjoubin-TehranMNikoozadehASavardashtakiATGF-β and WNT signaling pathways in cardiac fibrosis: Non-coding RNAs come into focusCell Commun Signal.2020188710.1186/s12964-020-00555-4728169032517807Search in Google Scholar
Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol. 2011; 51: 600–606.DobaczewskiMChenWFrangogiannisNGTransforming growth factor (TGF)-β signaling in cardiac remodelingJ Mol Cell Cardiol.20115160060610.1016/j.yjmcc.2010.10.033307243721059352Search in Google Scholar
Hu HH, Chen DQ, Wang YN, Feng YL, Cao G, Vaziri ND, Zhao YY. New insights into TGF-β/Smad signaling in tissue fibrosis. Chem Biol Interact. 2018; 292: 76–83.HuHHChenDQWangYNFengYLCaoGVaziriNDZhaoYYNew insights into TGF-β/Smad signaling in tissue fibrosisChem Biol Interact.2018292768310.1016/j.cbi.2018.07.00830017632Search in Google Scholar
Biasucci LM, Maino A, Grimaldi MC, Cappannoli L, Aspromonte N. Novel biomarkers in heart failure: New insight in pathophysiology and clinical perspective. J Clin Med. 2021; 10: 2771.BiasucciLMMainoAGrimaldiMCCappannoliLAspromonteNNovel biomarkers in heart failure: New insight in pathophysiology and clinical perspectiveJ Clin Med.202110277110.3390/jcm10132771826852434202603Search in Google Scholar
Osokina A, Karetnikova V, Polikutina O, Ivanova A, Gruzdeva O, Dyleva Y, Kokov A, Brel N, Pecherina T, Barbarash O. Prognostic potential of cardiac structural and functional parameters and N-terminal pro-peptide of type III procollagen in predicting cardiac fibrosis one year after myocardial infarction with preserved left ventricular ejection fraction. Aging. 2021; 13: 194–203.OsokinaAKaretnikovaVPolikutinaOIvanovaAGruzdevaODylevaYKokovABrelNPecherinaTBarbarashOPrognostic potential of cardiac structural and functional parameters and N-terminal pro-peptide of type III procollagen in predicting cardiac fibrosis one year after myocardial infarction with preserved left ventricular ejection fractionAging.20211319420310.18632/aging.202495783502333431713Search in Google Scholar
López B, González A, Díez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation. 2010; 121: 1645–1654.LópezBGonzálezADíezJCirculating biomarkers of collagen metabolism in cardiac diseasesCirculation.20101211645165410.1161/CIRCULATIONAHA.109.91277420385961Search in Google Scholar
Rosenberg JH, Werner JH, Plitt GD, Noble VV, Spring JT, Stephens BA, Siddique A, Merritt-Genore HL, Moulton MJ, Agrawal DK. Immunopathogenesis and biomarkers of recurrent atrial fibrillation following ablation therapy in patients with preexisting atrial fibrillation. Expert Rev Cardiovasc Ther. 2019; 17: 193–207.RosenbergJHWernerJHPlittGDNobleVVSpringJTStephensBASiddiqueAMerritt-GenoreHLMoultonMJAgrawalDKImmunopathogenesis and biomarkers of recurrent atrial fibrillation following ablation therapy in patients with preexisting atrial fibrillationExpert Rev Cardiovasc Ther.20191719320710.1080/14779072.2019.1562902638662930580643Search in Google Scholar